Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

CATIE and CUtLASS: can we handle the truth?

Lewis S, Lieberman J.

Br J Psychiatry. 2008 Mar;192(3):161-3. doi: 10.1192/bjp.bp.107.037218.

2.
4.

Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.

Foussias G, Remington G.

Can J Psychiatry. 2010 Mar;55(3):117-25. Review.

PMID:
20370961
5.

Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

Leucht S, Kissling W, Davis JM.

Psychol Med. 2009 Oct;39(10):1591-602. doi: 10.1017/S0033291709005455. Epub 2009 Apr 1. Review.

PMID:
19335931
6.

Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials.

Pecenak J.

Neuro Endocrinol Lett. 2007 Feb;28 Suppl 1:49-70. Review.

PMID:
17262007
7.

[Refractory schizophrenia].

Elkis H, Meltzer HY.

Rev Bras Psiquiatr. 2007 Oct;29 Suppl 2:S41-7. Review. Portuguese.

8.

Evidence-based management of schizophrenia.

Camprubi M, Dratcu L.

Hosp Med. 2004 Apr;65(4):201-5. Review.

PMID:
15127672
9.

[Clozapine in the treatment of under-age schizophrenia].

Haapasalo-Pesu KM.

Duodecim. 2009;125(15):1635-8. Review. Finnish.

PMID:
19769179
10.

The case against antipsychotic drugs: a 50-year record of doing more harm than good.

Whitaker R.

Med Hypotheses. 2004;62(1):5-13. Review.

PMID:
14728997
11.

[Pharmacotherapy for schizophrenia: are newer drugs truly superior?].

Ohmori T.

Seishin Shinkeigaku Zasshi. 2013;115(7):774-81. Review. Japanese.

PMID:
24050021
12.

Use and safety of antipsychotic drugs during pregnancy.

Einarson A, Boskovic R.

J Psychiatr Pract. 2009 May;15(3):183-92. doi: 10.1097/01.pra.0000351878.45260.94. Review.

PMID:
19461391
13.

[Increased level of knowledge within suicide prevention wanted. A literature review of evidence-based studies].

Rutz EM, Wasserman D, Stain R.

Lakartidningen. 2009 May 20-Jun 2;106(21-22):1480-4. Review. Swedish. No abstract available.

PMID:
19579437
14.

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.

Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K.

Br J Psychiatry. 2008 Jun;192(6):406-11. doi: 10.1192/bjp.bp.107.037184. Review.

15.

Emerging drugs for schizophrenia.

Agid O, Kapur S, Remington G.

Expert Opin Emerg Drugs. 2008 Sep;13(3):479-95. doi: 10.1517/14728214.13.3.479 . Review.

PMID:
18764724
16.

Guidelines for the use of clozapine in individuals with developmental disabilities.

Sabaawi M, Singh NN, de Leon J.

Res Dev Disabil. 2006 May-Jun;27(3):309-36. Epub 2005 Jul 22. Review.

PMID:
16040229
17.

Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.

Stroup TS, Alves WM, Hamer RM, Lieberman JA.

Nat Rev Drug Discov. 2006 Feb;5(2):133-46. Review.

PMID:
16518380
18.

Developments in the pharmacological treatment of schizophrenia.

Kuperberg G, Kerwin R, Murray R.

Expert Opin Investig Drugs. 2002 Oct;11(10):1335-41. Review.

PMID:
12387698
19.

Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics.

Oliveira IR, Nunes PM, Coutinho DM, Sena EP.

Rev Bras Psiquiatr. 2009 Mar;31(1):52-6. Review.

20.

Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities.

de Leon J, Greenlee B, Barber J, Sabaawi M, Singh NN.

Res Dev Disabil. 2009 Jul-Aug;30(4):613-69. doi: 10.1016/j.ridd.2008.10.010. Epub 2008 Dec 11. Review.

PMID:
19084370

Supplemental Content

Support Center